# Hormones Inflammation and Thrombosis

Study · id `cardio:ct-nct01875185` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01875185](<https://clinicaltrials.gov/study/NCT01875185>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01875185

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 100 participants.

## Technical summary

Registry record NCT01875185. Allocation not applicable; no masking; primary purpose diagnostic. Start 2012-12 (registry gives no type); primary completion 2013-11 (actual). Results posted on 2018-05-07.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT01875185, source copy `cardio:ctgov-nct01875185-2018-05-07`, retrieved 2026-10-31)
- Start date: 2012-12 (registry gives no type) (ClinicalTrials.gov record NCT01875185, source copy `cardio:ctgov-nct01875185-2018-05-07`, retrieved 2026-10-31)
- Primary completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01875185, source copy `cardio:ctgov-nct01875185-2018-05-07`, retrieved 2026-10-31)
- Completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01875185, source copy `cardio:ctgov-nct01875185-2018-05-07`, retrieved 2026-10-31)
- Results first posted: 2018-05-07 (ClinicalTrials.gov record NCT01875185, source copy `cardio:ctgov-nct01875185-2018-05-07`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01875185, source copy `cardio:ctgov-nct01875185-2018-05-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01875185-2018-05-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Hormones Inflammation and Thrombosis
- Acronym: HIT2
- Condition: Acute Coronary Syndrome
- Condition: Thrombosis
- Intervention (Drug): Aspirin 81 mg
- Lead sponsor: Johns Hopkins University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Johns Hopkins University (`cardio:org-johns-hopkins-university`)

## Provenance

Content hash: bc423fc5f6c76aa07aeb0a21b3cf713688e2cb4643881bb3184ff9707ad3af0d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
